Evidence mapPaperPMID 29941498Full record

Trial reportDiabetes care2018

Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test.

RISE Consortium

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01779375. Cited by 79 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 2 pooled it
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01779375 phase3completed

Restoring Insulin Secretion Pediatric Medication Study

Ran2013Enrolled91Registered outcomes6Posted comparisons3ConditionsPrediabetes, Type 2 DiabetesArmsGlargine, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Metformin monotherapy for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Once-Weekly Exenatide in Youth With Type 2 Diabetes.Diabetes care · 2022 · on this map
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

RISE Consortium
The Coordinating Center · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · 1986 to 2025
$12.6M
Yale Diabetes Research CenterP30DK045735 · YALE UNIVERSITY · 1993 to 2025
$10.2M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2025 to 2025
$10.1M
Yale Clinical and Translational Science AwardUL1TR001863 · YALE UNIVERSITY · 2025 to 2025
$9.9M
Southern California Clinical and Translational Science InstituteUL1TR001855 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2025 to 2025
$9.1M
Translation CoreP30DK097512 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$1.7M
Physiology CoreP30DK020595 · UNIVERSITY OF CHICAGO · 2025 to 2025
$1.4M
J. NRSA Training CoreTL1TR001858 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2025 to 2025
$930k
The Next Generation of Innovative Cardiovascular Clinical/Translational ResearchersK24HL145076 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KRISTEN Jane NADEAU · 2022 to 2023
$230k
NCATS NIH HHS TL1 TR001107NCATS NIH HHS TL1 TR001858NCATS NIH HHS UL1 TR000430NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001108NCATS NIH HHS UL1 TR001855NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR001863NHLBI NIH HHS K24 HL145076NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020595NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK097512NIDDK NIH HHS U01 DK094406NIDDK NIH HHS U01 DK094430NIDDK NIH HHS U01 DK094431NIDDK NIH HHS U01 DK094438NIDDK NIH HHS U01 DK094467
6 · The paper itself

Abstract

objectiveTo compare oral glucose tolerance test (OGTT) glucose, C-peptide, and insulin responses and insulin sensitivity in youth and adults with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes. RESEARCH DESIGN AND

methodsA total of 66 youth (80.3% with IGT) and 355 adults (70.7% with IGT) underwent a 3-h OGTT to assess

resultsFasting, 2-h glucose, and G-iAUC were similar in both age-groups, but youth had ∼50% lower 1/fasting insulin (

conclusionsThe balance between insulin sensitivity and β-cell responses differs between youth and adults with IGT or recently diagnosed type 2 diabetes. Despite similar postload glucose levels, youth demonstrate greater C-peptide and insulin responses that exceed what is needed to compensate for their lower insulin sensitivity. Longitudinal studies are required to determine whether this feature contributes to a more rapid decline in β-cell function in youth with dysglycemia.

Indexed as

Insulin ResistanceAdolescentAdultAgedBlood GlucoseChildC-PeptideDiabetes Mellitus, Type 2FastingFemaleGlucose IntoleranceGlucose Tolerance TestHumansInsulinInsulin-Secreting CellsMaleBlood GlucoseC-PeptideInsulin

Identifiers

PMID29941498
PMCPMC6054494
OpenAlexW4231308497

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.